Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-12-04FDA Approved: THALOMID — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for Thalomid (thalidomide) submitted by Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2019-12-03Clinical Trial Update: Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3 [Phase 2]
Phase 2 clinical trial update for masitinib in relapse/refractory multiple myeloma with t(4/14) translocation, FGFR3 expression status.
-
CLINICAL_TRIALS trial_result · 2019-11-29Clinical Trial Update: RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma [Phase 4]
Phase 4 clinical trial update comparing RDD versus VDD in newly diagnosed multiple myeloma patients.
-
CLINICAL_TRIALS trial_result · 2019-11-21Clinical Trial Update: Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma [Phase 3]
A Phase 3 trial evaluating carfilzomib with dexamethasone in Chinese patients with relapsed and refractory multiple myeloma has completed wi…
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma [Phase 3]
Phase 3 trial evaluating efficacy and safety of three thalidomide doses for relapsed/refractory multiple myeloma has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial update evaluating BCMA-PD1-CART cells for safety and efficacy in relapsed/refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2019-11-18Clinical Trial Update: Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid [NA]
Clinical trial investigating simvastatin and zoledronic acid for overcoming chemotherapy resistance in refractory multiple myeloma; study te…
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2, Phase 3]
Phase 2/3 trial evaluating JNJ-63723283 in combination with daratumumab vs daratumumab alone in relapsed or refractory multiple myeloma has …
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 2]
Phase 2 trial updates safety and efficacy of single-agent CC-5013 in relapsed and refractory multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: CDC-501 Therapy in Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial update of CDC-501 therapy in relapsed or refractory multiple myeloma completed.
-
CLINICAL_TRIALS trial_result · 2019-11-12Clinical Trial Update: Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year [Phase 2]
Open-label extended access study of lenalidomide plus dexamethasone in Chinese patients with relapsed/refractory multiple myeloma who had at…
-
CLINICAL_TRIALS trial_result · 2019-11-08Clinical Trial Update: Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma [Phase 3]
Phase 3 trial update evaluating subcutaneous and intravenous Velcade in combination with dexamethasone for Chinese patients with relapsed an…
-
CLINICAL_TRIALS trial_result · 2019-11-04Clinical Trial Update: Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating chemotherapy and peripheral stem cell transplantation followed by immunotherapy for multiple myeloma; st…
-
FDA approval · 2019-10-30FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for POMALYST (pomalidomide) submitted by Celgene Corporation.
-
FDA approval · 2019-10-28FDA Approved: EMPLICITI — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
The FDA approved a supplemental application for EMPLICITI (elotuzumab) from E.R. Squibb & Sons, L.L.C., resulting in a labeling/indication u…
-
CLINICAL_TRIALS trial_result · 2019-10-22Clinical Trial Update: Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib [Phase 2]
Phase 2 trial update on using glutamine to prevent peripheral neuropathy in patients with multiple myeloma treated with bortezomib; study st…
-
CLINICAL_TRIALS trial_result · 2019-10-22Clinical Trial Update: Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant in Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 trial evaluating lenalidomide and high-dose melphalan followed by autologous stem cell transplant in multiple myeloma has complete…
-
CLINICAL_TRIALS trial_result · 2019-10-18Clinical Trial Update: Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma [Phase 2, Phase 3]
A phase 2/3 clinical trial comparing thalidomide 100 mg/day versus 400 mg/day in relapse-refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2019-10-17Clinical Trial Update: Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating peripheral stem cell transplantation with combination chemotherapy in patients with multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2019-10-17Clinical Trial Update: Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating oblimersen, thalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2019-10-17Clinical Trial Update: Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating peripheral stem cell transplantation with combination chemotherapy in patients with multiple myeloma has c…
-
CLINICAL_TRIALS trial_result · 2019-10-15Clinical Trial Update: A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies [Phase 2]
Phase 2 study evaluating bone marrow transplantation from fully matched relatives as donors for hematologic malignancies has completed; resu…
-
CLINICAL_TRIALS trial_result · 2019-10-15Clinical Trial Update: Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma [Phase 4]
A Phase 4 trial evaluating lenalidomide and dexamethasone with or without stem cell transplant in patients with multiple myeloma has complet…
-
CLINICAL_TRIALS trial_result · 2019-10-14Clinical Trial Update: Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma [Phase 1]
Phase 1 trial evaluating total marrow irradiation with high-dose melphalan before autologous transplant in multiple myeloma; the study statu…
-
FDA label_change · 2019-10-08FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) by Teva Pharmaceuticals to update its labeling.